Study on the Diagnosis and Management of CLL in Italy by GIMEMA
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Small Lymphocytic Lymphoma
Related studies linked through entity extraction aliases.
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
- Status
- COMPLETED
- Phase
- N/A
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- N/A
Safe Accelerated Venetoclax Escalation in CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Status
- RECRUITING
- Phase
- PHASE1
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- N/A
A Study of FCN-338 in Patients With Chronic CLL/SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Status
- WITHDRAWN
- Phase
- PHASE2
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
- Status
- UNKNOWN
- Phase
- PHASE3
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
- Status
- RECRUITING
- Phase
- PHASE2
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2